Tech Company Financing Transactions
Ashvattha Therapeutics Funding Round
Huadong Medicine, Natural Capital Investment Fund and Plum Alley Investments participated in a $69 million Series B venture round for Ashvattha Therapeutics. The round was announced on 4/27/2022.
Transaction Overview
Company Name
Announced On
4/27/2022
Transaction Type
Venture Equity
Amount
$69,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds will support the advancement of Ashvattha's pipeline of hydroxyl dendrimer therapeutics (HDTs), including multiple clinical stage programs.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1235 Radio Road Suite 200
Redwood City, CA 94065
USA
Redwood City, CA 94065
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Developer of novel therapeutics platform designed to treat the unmet medical needs in oncology, ophthalmology, and inflammatory diseases. The company's platform consists of hydroxyl dendrimers that selectively target actively endocytosing cells such as reactive microglia and macrophages responsible for chronic inflammation and disease progression within the body, enabling medical practitioners to treat patients with improved efficacy and reduced side effects.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jeffrey Cleland
Chief Technical Officer
Kannan Rangaramanujam
Co-Founder
Sujatha Kannan
Browse more venture capital transactions:
Prev: 4/27/2022: Enveil venture capital transaction
Next: 4/27/2022: Womp venture capital transaction
Share this article
News on VC Transactions
We do our best to report on all VC transactions involving tech companies. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs